<DOC>
	<DOC>NCT00063869</DOC>
	<brief_summary>The objective of the study is to evaluate the safety and efficacy of etanercept in comparison with placebo in a double-blind, parallel, randomized fashion in subjects with idiopathic pulmonary fibrosis (IPF) who failed previous therapy. The treatment period will be up to 1 year. The primary objective is evaluation of safety and efficacy. Secondary: The secondary objective is to evaluate quality of life (QoL) and pharmacokinetics (PK).</brief_summary>
	<brief_title>Study Evaluating the Safety and Efficacy of Etanercept in Patients With Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Diagnosis of IPF based on American Thoracic Society (ATS) guidelines Subjects with endstage Previous treatment with etanercept or other TNF antagonists (eg, a TNF monoclonal antibody or a soluble TNFreceptor) Receipt of any investigational drug or biological agent within 4 weeks of screening visit</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Idiopathic Pulmonary Fibrosis</keyword>
	<keyword>Fibrosis, Pulmonary</keyword>
	<keyword>Pulmonary Fibroses</keyword>
	<keyword>Fibroses, Pulmonary</keyword>
</DOC>